Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Omthera Pharmaceuticals

AstraZeneca AZ

AZ sells rare cancer drug to Sanofi

French firm’s rare disease unit Genzyme will pay $300m for the treatment

- PMLiVE

AstraZeneca forms ‘smart inhaler’ digital health partnership

Follows separate deal for a health coaching app for heart attack patients

- PMLiVE

The Partners appoints new creative director

Award-winning Peter Henshaw joins from InVentive Europe

AstraZeneca AZ

Iressa set for US market return after FDA approval

AstraZeneca'slung cancer drug wins green light for EGFR tumours

- PMLiVE

AstraZeneca’s Amie Baker wins Communiquétor 2015 award

And the UK pharma company takes home In-House team of the Year

- PMLiVE

Executive leak continues at AZ as another head jumps ship

James Ward-Lilley will become CEO of lung drug specialist Vectura

- PMLiVE

AstraZeneca and its diabetes plans

Director of marketing Chris Boulton is bullish on its prospects

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

Senior AstraZeneca exec jumps ship to small biotech

Briggs Morrison unexpectedly leaves the UK firm

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

- PMLiVE

Merck & Co’s diabetes drug Januvia cleared by CV safety trial

Concerns over the DPP-4 inhibitor 'put to bed' by TECOS cardiovascular trial

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links